US Stock MarketDetailed Quotes

EYPT EyePoint Pharmaceuticals

Watchlist
  • 6.060
  • -0.180-2.88%
Close Mar 26 16:00 ET
  • 6.050
  • -0.010-0.17%
Pre 08:36 ET
416.50MMarket Cap-2.61P/E (TTM)

About EyePoint Pharmaceuticals Company

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Company Profile

SymbolEYPT
Company NameEyePoint Pharmaceuticals
Listing DateJan 27, 2005
Founded1987
CEODr. Jay S. Duker, M.D.
MarketNASDAQ
Employees165
Fiscal Year Ends12-31
Address480 Pleasant Street,Suite A-210
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-617-926-5000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jay S. Duker, M.D.
  • Director, President and Chief Executive Officer
  • 2.92M
  • Dr. Ramiro Ribeiro, M.D.,PhD
  • Chief Medical Officer
  • --
  • George O. Elston
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • 1.78M
  • Nancy S. Lurker
  • Executive Vice Chairman of the Board
  • 3.74M
  • Dr. Goran A. Ando, M.D.
  • Chairman of the Board
  • 214.78K
  • Dr. Reginald Sanders, M.D.
  • Director
  • --
  • Fred Hassan
  • Director
  • --
  • Dr. John B. Landis, PhD
  • Director
  • 161.67K
  • Wendy F. DiCicco
  • Independent Director
  • 171.67K
  • Karen Zaderej
  • Independent Director
  • 149.17K
  • Stuart M. Duty
  • Independent Director
  • 381.10K

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More